Orexo AB (OSTO:ORX) GF Score : 54/100 (As of Dec. 15, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Orexo AB GF Score?

Orexo AB has the GF Score of 54, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 4/10
3. Growth Rank : 1/10
4. GF Value Rank : 6/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Orexo AB might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Orexo AB's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orexo AB's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's GF Score distribution charts can be found below:

* The bar in red indicates where Orexo AB's GF Score falls into.

Orexo AB (OSTO:ORX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Orexo AB GF Score Related Terms

Thank you for viewing the detailed overview of Orexo AB's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OSTO:ORX) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

ORXOY:USA ORXOF:USA C5G:Germany

Address

Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105

Website

https://www.orexo.com

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines